Abstract
IntroductionUse of the mechanically expandable transcatheter aortic valve (MEV) has been recently linked to increased risks of valve dysfunction and cardiovascular mortality. The risk of developing conduction disturbance with the MEV valve is well known, and the negative prognostic impact of permanent pacemaker implantation (PPI) after transcatheter aortic valve implantation is another consideration.AimThis study aimed to compare the mid-term survival of patients with MEV and self-expandable valves (SEV), and to examine survival of both groups according to the presence or absence of PPI.MethodsThis single-centre, retrospective, observational study examined data from MEV and SEV groups comprising 92 and 373 patients, respectively. The mean clinical follow-up was 2.5±1.7 years. Mortality information was obtained from the National Institutes of Health Information and Statistics.ResultsBaseline characteristics were comparable between the groups. The log-rank test showed higher cardiovascular mortality in the MEV group (p=0.042; the relative risk (RR) 1.594 (95% CI 1.013 to 2.508)). The Cox proportional hazards model identified MEV implantation as an independent predictor of cardiovascular mortality. The rate of PPI was twice as high in the MEV vs SEV group (33.7% vs 16.1%; p<0.001). We compared the survival of both groups according to the presence or absence of PPI and found higher mortality in the MEV group without PPI versus the SEV group without PPI (p=0.007; RR 2.156 (95% CI 1.213 to 3.831)). Survival did not differ in the groups with PPI.ConclusionsA higher mid-term cardiovascular mortality rate was observed with MEV versus SEV implants. Comparing both groups according to the presence or absence of PPI, we observed a higher mortality risk in patients with MEV without PPI than in SEV without PPI. In contrast, mortality did not differ between the groups when PPI was implanted.
Funder
Ministry of Health, Czech Republic–Conceptual Development of Research Organization, Motol University Hospital, Prague Czech Republic
Subject
Cardiology and Cardiovascular Medicine
Reference25 articles.
1. Long-Term Clinical and Echocardiographic Outcome After TAVR With the Mechanically Expanding Lotus Valve
2. Incidence and mechanisms of bioprosthetic dysfunction after transcatheter implantation of a mechanically-expandable heart valve
3. Mid-term outcomes of patients with Lotus and Evolut transcatheter valves
4. Boston scientific ANNOUNCES LOTUS edge™ aortic valve Systém voluntary recall and product discontinuation. Available: https://news.bostonscientific.com/2020-11-17-Boston-Scientific-Announces-LOTUS-Edge-TM-Aortic-Valve-System-Voluntary-Recall-and-Product-Discontinuation?_ga=2.254661645.40144748.1650958770-139210216.1640256942 [Accessed 17 Nov 2020].
5. Company announcement. Boston Scientific Announces LOTUS Edge™ aortic valve system voluntary recall and product discontinuation, Available: https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/boston-scientific-announces-lotus-edgetm-aortic-valve-system-voluntary-recall-and-product [Accessed 11 Jan 2021].